Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
G1 Therapeutics, Inc. (GTHX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
4
| Velleca Mark A. (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 57,286 shares
@ $1.9986, valued at
$114.5k
Sold 2,714 shares
@ $2.02, valued at
$5.5k
Exercised 57,286 options to buy
@ $0.39, valued at
$22.3k
Exercised 2,714 options to buy
@ $0.3, valued at
$814.2 |
|
| 07/07/2023 |
4
| Perry Andrew (Chief Commercial Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 355 shares
@ $2.4537, valued at
$871.1 |
|
| 07/07/2023 |
4
| MURDOCK TERRY L (COO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 1,361 shares
@ $2.4537, valued at
$3.3k
|
|
| 07/07/2023 |
4
| Malik Rajesh (Chief Medical Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 1,361 shares
@ $2.4537, valued at
$3.3k
|
|
| 07/07/2023 |
4
| Bailey John E. (Jack) Jr. (President and CEO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 2,719 shares
@ $2.4537, valued at
$6.7k
|
|
| 06/16/2023 |
4
| Sharpless Norman (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 06/16/2023 |
4
| Flowers Cynthia Louise (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 06/16/2023 |
4
| MUIR GLENN P (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 06/16/2023 |
4
| Lee Jacks (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 06/16/2023 |
4
| Secor Alicia (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 06/16/2023 |
4
| Nicholson Garry A (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
| 05/24/2023 |
3
| Thomas Monica R. (General Counsel) has filed a Form 3 on G1 Therapeutics, Inc. |
| 05/24/2023 |
4
| Thomas Monica R. (General Counsel) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 50,000 shares
@ $0
Granted 150,000 options to buy
@ $2.88, valued at
$432k
|
|
| 05/12/2023 |
4
| MURDOCK TERRY L (COO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 05/12/2023 |
4
| Avagliano Mark (Chief Business Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 05/12/2023 |
4
| Malik Rajesh (Chief Medical Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 05/12/2023 |
4
| Umstead John V. (CFO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 05/12/2023 |
4
| Perry Andrew (Chief Commercial Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 35,000 shares
@ $0 |
|
| 05/12/2023 |
4
| Bailey John E. (Jack) Jr. (President and CEO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 160,000 shares
@ $0 |
|
| 03/17/2023 |
4
| Umstead John V. (CFO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 50,000 shares
@ $0
Granted 100,000 options to buy
@ $3.27, valued at
$327k
|
|
| 03/17/2023 |
3
| Umstead John V. (CFO) has filed a Form 3 on G1 Therapeutics, Inc. |
| 01/05/2023 |
4
| Moses Jennifer K. (CFO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 22,300 shares
@ $0
Sold 1,639 shares
@ $5.5756, valued at
$9.1k
Sold 729 shares
@ $5.4075, valued at
$3.9k
Granted 44,600 options to buy
@ $5.73, valued at
$255.6k
|
|
| 01/05/2023 |
4
| MURDOCK TERRY L (COO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 17,900 shares
@ $0
Sold 1,639 shares
@ $5.5756, valued at
$9.1k
Sold 729 shares
@ $5.4075, valued at
$3.9k
Granted 35,700 options to buy
@ $5.73, valued at
$204.6k
|
|
| 01/05/2023 |
4
| Perry Andrew (Chief Commercial Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 16,100 shares
@ $0
Sold 820 shares
@ $5.5756, valued at
$4.6k
Granted 32,100 options to buy
@ $5.73, valued at
$183.9k
|
|
| 01/05/2023 |
4
| Malik Rajesh (Chief Medical Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 17,900 shares
@ $0
Sold 1,639 shares
@ $5.5756, valued at
$9.1k
Sold 729 shares
@ $5.4075, valued at
$3.9k
Granted 35,700 options to buy
@ $5.73, valued at
$204.6k
|
|
| 01/05/2023 |
4
| Avagliano Mark (Chief Business Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 20,600 shares
@ $0
Granted 41,100 options to buy
@ $5.73, valued at
$235.5k
|
|
| 01/05/2023 |
4
| Hanson James S. (General Counsel) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 17,900 shares
@ $0
Sold 1,639 shares
@ $5.5756, valued at
$9.1k
Sold 729 shares
@ $5.4075, valued at
$3.9k
Granted 35,700 options to buy
@ $5.73, valued at
$204.6k
|
|
| 01/05/2023 |
4
| Bailey John E. (Jack) Jr. (President and CEO) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Granted 80,700 shares
@ $0
Sold 32,019 shares
@ $5.8544, valued at
$187.5k
Sold 5,607 shares
@ $5.5756, valued at
$31.3k
Granted 161,300 options to buy
@ $5.73, valued at
$924.2k
|
|
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/16/2022 |
4
| Malik Rajesh (Chief Medical Officer) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 18,000 shares
@ $15.7081, valued at
$282.7k
Exercised 18,000 options to buy
@ $0.39, valued at
$7k
|
|
| 08/18/2022 |
4
| Velleca Mark A. (Director) has filed a Form 4 on G1 Therapeutics, Inc.|
Txns:
| Sold 80,000 shares
@ $12.6363, valued at
$1M
Exercised 80,000 options to buy
@ $0.39, valued at
$31.2k
|
|
| 08/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|